At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December 2015, Sibylle Loibl, MD, PhD, from the German Breast Group, Neu-Isenburg, Germany, discusses changes in tumour expression of HER2 and hormone receptor status and pathological complete response (pCR) after neoadjuvant chemotherapy in a Japanese breast cancer registry.
Tumour biomarker changes after neoadjuvant chemotherapy in breast cancer
25 May 2016
Oncology
Rate this content's potential impact on patient outcomes
Average rating / 5. Vote count:
No votes so far! Be the first to rate this content.